WO2004072305A3 - Atlastine - Google Patents

Atlastine Download PDF

Info

Publication number
WO2004072305A3
WO2004072305A3 PCT/US2004/004013 US2004004013W WO2004072305A3 WO 2004072305 A3 WO2004072305 A3 WO 2004072305A3 US 2004004013 W US2004004013 W US 2004004013W WO 2004072305 A3 WO2004072305 A3 WO 2004072305A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
atlastin
present
mutations
named
Prior art date
Application number
PCT/US2004/004013
Other languages
English (en)
Other versions
WO2004072305A2 (fr
Inventor
John K Fink
Xinping Zhao
Original Assignee
Univ Michigan
John K Fink
Xinping Zhao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, John K Fink, Xinping Zhao filed Critical Univ Michigan
Publication of WO2004072305A2 publication Critical patent/WO2004072305A2/fr
Publication of WO2004072305A3 publication Critical patent/WO2004072305A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4722—G-proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La présente invention concerne des méthodes et des compositions d'un nouveau gène et du peptide codé par le gène. Des mutations dans le gène, appelées atlastine, sont des facteurs de la maladie héréditaire, la paraplégie spastique, et d'autres troubles liés. Les méthodes et compositions de cette invention sont utilisées dans la recherche, le diagnostic et le traitement de ces maladies invalidantes.
PCT/US2004/004013 2003-02-11 2004-02-11 Atlastine WO2004072305A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/364,748 2003-02-11
US10/364,748 US7582425B2 (en) 2001-09-21 2003-02-11 Atlastin

Publications (2)

Publication Number Publication Date
WO2004072305A2 WO2004072305A2 (fr) 2004-08-26
WO2004072305A3 true WO2004072305A3 (fr) 2004-10-21

Family

ID=32867979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/004013 WO2004072305A2 (fr) 2003-02-11 2004-02-11 Atlastine

Country Status (2)

Country Link
US (2) US7582425B2 (fr)
WO (1) WO2004072305A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582425B2 (en) * 2001-09-21 2009-09-01 The Regents Of The University Of Michigan Atlastin
JP5312314B2 (ja) * 2006-03-30 2013-10-09 デューク ユニヴァーシティー 家族性痙性対麻痺の根底にある新規遺伝子の同定

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026566A2 (fr) * 2001-09-21 2003-04-03 The Regents Of The University Of Michigan Atlastine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
DE2938534A1 (de) 1979-09-24 1981-04-23 Bayer Ag, 5090 Leverkusen Acylierte triazolyl-(gamma)-fluorpinakolyl-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4435504A (en) 1982-07-15 1984-03-06 Syva Company Immunochromatographic assay with support having bound "MIP" and second enzyme
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5925525A (en) 1989-06-07 1999-07-20 Affymetrix, Inc. Method of identifying nucleotide differences
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
CA2039921A1 (fr) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfert et expression de la sequence d'adn dans les cellules du systeme nerveux central a l'aide de mutants du virus de l'herpes, avec deletions chez les genes en vue de repliquer le virus
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5726010A (en) 1991-07-31 1998-03-10 Idexx Laboratories, Inc. Reversible flow chromatographic binding assay
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5994069A (en) 1996-01-24 1999-11-30 Third Wave Technologies, Inc. Detection of nucleic acids by multiple sequential invasive cleavages
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US6051380A (en) 1993-11-01 2000-04-18 Nanogen, Inc. Methods and procedures for molecular biological analysis and diagnostics
US6017696A (en) 1993-11-01 2000-01-25 Nanogen, Inc. Methods for electronic stringency control for molecular biological analysis and diagnostics
US5843654A (en) 1992-12-07 1998-12-01 Third Wave Technologies, Inc. Rapid detection of mutations in the p53 gene
US5888780A (en) 1992-12-07 1999-03-30 Third Wave Technologies, Inc. Rapid detection and identification of nucleic acid variants
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
CA2168202A1 (fr) 1993-07-30 1995-03-16 Joseph Dougherty Transfert genique efficace aboutissant a des lymphocytes primaires
US6045996A (en) 1993-10-26 2000-04-04 Affymetrix, Inc. Hybridization assays on oligonucleotide arrays
US6068818A (en) 1993-11-01 2000-05-30 Nanogen, Inc. Multicomponent devices for molecular biological analysis and diagnostics
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
EP0754240B1 (fr) 1994-02-07 2003-08-20 Beckman Coulter, Inc. Analyse d'elements genetiques induite par la ligase/polymerase de polymorphismes de mononucleotides et son utilisation dans des analyses genetiques
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CA2134838A1 (fr) 1994-09-12 1996-03-13 Lawson Gibson Wideman Composition de caoutchouc renforcee de silice
US5770567A (en) 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US5605789A (en) 1994-12-22 1997-02-25 Eastman Kodak Company Iodochloride emulsions containing iodonium salts having high sensitivity and low fog
KR970022316A (ko) 1995-10-27 1997-05-28 후루야 아끼라 빌리루빈의 정량 방법
US5985557A (en) 1996-01-24 1999-11-16 Third Wave Technologies, Inc. Invasive cleavage of nucleic acids
US5777324A (en) 1996-09-19 1998-07-07 Sequenom, Inc. Method and apparatus for maldi analysis
US5919626A (en) 1997-06-06 1999-07-06 Orchid Bio Computer, Inc. Attachment of unmodified nucleic acids to silanized solid phase surfaces
US6125383A (en) 1997-06-11 2000-09-26 Netgenics Corp. Research system using multi-platform object oriented program language for providing objects at runtime for creating and manipulating biological or chemical data
WO1999040189A2 (fr) 1998-02-09 1999-08-12 Genset ADNc CODANT DES PROTEINES SECRETEES
AU2390800A (en) 1998-12-23 2000-07-12 Genetics Institute Inc. Secreted proteins
US7582425B2 (en) * 2001-09-21 2009-09-01 The Regents Of The University Of Michigan Atlastin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003026566A2 (fr) * 2001-09-21 2003-04-03 The Regents Of The University Of Michigan Atlastine

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALVARADO D M ET AL: "Atlastin gene analysis in early onset hereditary spastic paraplegia", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 69, no. 4 Supplement, October 2001 (2001-10-01), & 51ST ANNUAL MEETING OF THE AMERICAN SOCIETY OF HUMAN GENETICS; SAN DIEGO, CALIFORNIA, USA; OCTOBER 12-16, 2001, pages 597, XP002290965, ISSN: 0002-9297 *
DATABASE EMBL 12 February 2002 (2002-02-12), ZHAO ET AL: "Homo sapiens GTPase mRNA complete cds", XP002291302, retrieved from EBI Database accession no. AY032844 *
MUGLIA M ET AL: "Further evidence that SPG3A gene mutations cause autosomal dominant hereditary spastic paraplegia", ANNALS OF NEUROLOGY, BOSTON, US, vol. 51, no. 6, June 2002 (2002-06-01), pages 794 - 795, XP002975283, ISSN: 0364-5134 *
SAUTER S M ET AL: "Novel mutations in the Atlastin gene (SPG3A) in families with autosomal dominant hereditary spastic paraplegia and evidence for late onset forms of HSP linked to the SPG3A locus.", HUMAN MUTATION. JAN 2004, vol. 23, no. 1, January 2004 (2004-01-01), pages 98, XP002291119, ISSN: 1098-1004 *
TESSA A ET AL: "SPG3A: An additional family carrying a new atlastin mutation.", NEUROLOGY. 24 DEC 2002, vol. 59, no. 12, 24 December 2002 (2002-12-24), pages 2002 - 2005, XP002290978, ISSN: 0028-3878 *
ZHAO X ET AL: "Mutations in a newly identified GTPase gene cause autosomal dominant hereditary spastic paraplegia", NATURE GENETICS, NATURE AMERICA, NEW YORK, US, vol. 29, November 2001 (2001-11-01), pages 326 - 328, XP002975282, ISSN: 1061-4036 *
ZHU PENG-PENG ET AL: "Cellular localization, oligomerization, and membrane association of the hereditary spastic paraplegia 3A (SPG3A) protein atlastin.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 5 DEC 2003, vol. 278, no. 49, 5 December 2003 (2003-12-05), pages 49063 - 49071, XP002291120, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2004072305A2 (fr) 2004-08-26
US7582425B2 (en) 2009-09-01
US20090215065A1 (en) 2009-08-27
US20030224968A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
WO2006035237A3 (fr) Procedes et compositions lies a la maladie d'alzheimer
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
WO2006003388A3 (fr) Compositions et procedes pour le traitement de troubles inflammatoires
WO2007024441A3 (fr) Compositions cellulaires enrichies destines a la combinaison de diverses populations cellulaires a base de cellules souches et de cellules progenitrices, leurs methodes d'utilisation, et methodes de mise en banque privee
WO2006092668A3 (fr) Compositions proteiques de cellules cutanees foetales pour le traitement d'affections, de troubles ou de maladies cutanes et procedes de fabrication et d'utilisation de celles-ci
WO2007109236A8 (fr) Empreintes digitales micro-arn pendant une mégacaryocytopoïese
WO2007117438A3 (fr) Méthodes de production d'une protéine fonctionnelle à partir d'un adn présentant une mutation non-sens et traitement des troubles associés
WO2004014222A3 (fr) Diagnostic et traitement de maladies engendrees par des anomalies propres au trajet de la sclerose tubereuse (de bourneville)
WO2006023452A3 (fr) Analogues de la cyclosporine utilises pour le traitement de troubles immunoregulateurs et de maladies respiratoires
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
WO2005004814A3 (fr) Sirt1 et troubles d'ordre genetique
WO2003057856A3 (fr) Proteines negatives dominantes et procedes associes
WO2005003103A3 (fr) Nouveaux heterocycles 2,4,6-trisubstitues et utilisations de ceux-ci
WO2007022642A3 (fr) Molecules anti-inflammatoires et leurs utilisations
WO2003026566A3 (fr) Atlastine
WO2006078336A3 (fr) Compositions et methodes permettant de traiter et de prevenir des maladies hyperproliferatives
WO2004081199A3 (fr) Nouvelles compositions et methodes de traitement de troubles du systeme immunitaire
WO2006050451A3 (fr) Methodes et compositions pour traiter des maladies des motoneurones
WO2006016172A3 (fr) Glycoproteine de surface
WO2004110365A3 (fr) Compositions et methodes destinees au traitement de maladies hepatiques
WO2004072305A3 (fr) Atlastine
WO2008125902A8 (fr) Diaphonie inflammatoire périphérique et neuronale
WO2005022164A3 (fr) Agents diagnostiques et agents therapeutiques destines a des maladies associees a la kallikreine 8 (klk8)
WO2009091932A3 (fr) Traitement de la démence légère du type de la maladie d'alzheimer
WO2004042018A3 (fr) Neurones de dopamine provenant de cellules souches embryonnaires humaines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase